泽璟制药：公司注射用ZGGS34获得美国食品药品监督管理局颁发的临床试验批准

Core Viewpoint - ZaiJing Pharmaceutical's injectable ZGGS34 has received clinical trial approval from the FDA for the treatment of advanced solid tumors, but this approval will not have a significant impact on the company's recent performance due to the lengthy and uncertain nature of drug development [1] Group 1 - The FDA has granted clinical trial approval for ZaiJing Pharmaceutical's injectable ZGGS34 [1] - The drug is intended for the treatment of advanced solid tumors [1] - The approval is not expected to significantly affect the company's recent performance [1] Group 2 - The drug development process is characterized by long cycles, multiple approval stages, and substantial research investment [1] - The company faces various uncertainties that could impact the drug's development [1]